News
-
CSL pre-empts TGA review outcome
- Fri Oct 16
Company moves to withdraw its rare autoimmune therapy from the Australian market following international safety concerns with trial data.
Read more -
‘Australia risks falling through the cracks’: global CEO
- Wed Oct 14
argenx’s Karen Massey says China and the US are in a race to attract pharma investment, and Australia has a small window to cement its place in the global ecosystem.
Read more -
Should pharma be judged on patient access?
- Wed Oct 14
ANZ patient organisations marked pharma down for failing to deliver funded access to medicines. Companies say it’s a fair call, but access is a shared responsibility.
Read more -
Guess who’s beefed up their comms muscle?
- Wed Oct 14
Medicines Australia has joined a leading company in attracting top communications talent as a local leader gets a big promotion.
Read more -
MS rapid review: how industry responded
- Wed Oct 14
At least four companies have made submissions to PBAC’s ‘rapid review’ of MS medicines, but only one company outlined its position.
Read more -
Which pharma companies love lobbyists?
- Mon Oct 12
Some government relations teams are self-sufficient; others lean heavily on lobbyists for their political work. We reveal the companies that use the most lobbyists.
Read more -
Expectation gap undermining patient partnerships
- Mon Oct 12
EXCLUSIVE: Pharma companies are trying to build meaningful relationships with patients, so why do many ANZ patient organisations feel they are failing to deliver? Companies explain.
Read more -
Guild calls for ‘review’ of LillyDirect
- Mon Oct 12
Guild calls for government examination of ‘vertically-integrated healthcare models’, including direct-to-consumer models like LillyDirect.
Read more